Intravenous (IV) Iron Formulations Market To Reach USD 6.4 Billion By 2032

The intravenous (IV) iron formulations market is experiencing significant growth due to technological advancements.

Fort Collins, Colorado, Dec. 05, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, The Intravenous (IV) Iron Formulations Market size was valued at USD 3.1 Billion in 2022 and is expected to exhibit a CAGR of 7.6% to reach USD 6.4 Billion by 2032.

IV iron formulations are in demand due to their safety, efficacy, faster absorption, less adverse effects, and higher bioavailability. They are administered directly into the bloodstream and are used to treat conditions such as chronic kidney disease, cancer, and inflammatory bowel disease.

These diseases cause less iron absorption through the oral route, increasing the demand for intravenous iron formulations. Chronic kidney disease affects over 10% of the global population, which amounts to more than 800 million individuals.

Anemia in women, cardiovascular diseases, and chronic kidney disorders are on the rise, creating opportunities for IV iron formulations. Increased cancer cases also present a scope for R&D in this area. Awareness campaigns can help expand the market to emerging economies with higher rates of iron deficiency anemia.

Request Sample Report:

Segmentation Overview:

The global intravenous (IV) iron formulations market has been segmented into product, application, and region. Ferric carboxymaltose is the leading drug on the market and is safe for late pregnancy and heart failure patients. Its dominance is due to its safety and efficacy. IV iron formulations for chronic kidney disease also dominate the market.

Buy This Research Report:

Intravenous (IV) Iron Formulations Market Report Highlights:

  • The global intravenous (IV) iron formulations market growth is anticipated at a CAGR of 7.6% by 2032.
  • IV iron formulations are in demand due to their faster absorption and safety, used to treat chronic conditions like kidney disease and cancer.
  • North America leads the market due to continuous drug development and USFDA approval, such as the approval of Injectafer for treating iron deficiency in adult patients with heart failure.
  • Some prominent players in the intravenous (IV) iron formulations market report include Zydus group, AbbVie Inc., Sanofi, Daiichi Sankyo Company Ltd, AMAG Pharmaceuticals (Covis Pharma), Vifor Pharma Management Ltd (CSL), Pharmacosmos A/S

Industry Trends and Insights:

-          Zydus Lifesciences acquired LiqMeds Group for £68 million.

-          Sanofi completed its deal with Janssen Pharmaceuticals for ExPEC9V, a vaccine candidate for extraintestinal pathogenic E. coli. 

Looking Exclusively For Region/Country Specific Report?


Ask For Discount

Intravenous (IV) Iron Formulations Market Segmentation:

By Product: Dextran, Iron Sucrose, Ferric Carboxymaltose, Others

By Application: Chronic Kidney Diseases, Inflammatory Bowel Disease

By Region: North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. 

About DataHorizzon Research:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.



Ph: +1-970-672-0390


Follow Us: LinkedIn 


Recent Publications

Clear Aligners Market 2023 to 2032

Medical Waste Management Market 2023 to 2032

eClinical Solutions Market 2023 to 2032

Pharmaceutical Packaging Market 2023 to 2032

Regenerative Medicine Market 2023 to 2032


Contact Data